Sam O Pharmaceutical Increases Stake in Aminologics to 36.58% via CB Acquisition and Open Market Purchases to Strengthen Management Control
Sam O Pharmaceutical increased its stake in Aminologics by 5.32 percentage points from 31.26% to 36.58%.
The increase of 6,576,260 shares consists of 5,224,660 newly acquired convertible bonds plus open market purchases by specially related parties.
The CB acquisition cost of 5 billion won was fully funded from internal resources, and conversion would add 5.22 million potential shares, leading to potential dilution for minority shareholders.
The stated purpose is to exercise management influence, including rights to appoint directors and change capital structure.
[AI Summary]Sam O Pharmaceutical's stake increase is a defensive capital allocation to consolidate control, but the potential dilution from convertible bonds reaches 5.95% of outstanding shares, raising minority dilution concerns. While self-funded and financially sound, the lack of growth-oriented capital deployment limits upside catalyst for the stock.